Biotech pair looks to FDA approval of thrombin drugs this year

02/3/2007 | CNNMoney

Two biotechs are awaiting FDA approval this year for products that could challenge King Pharmaceuticals' control of the market for thrombin drugs used in surgery. Omrix BioPharmaceuticals created thrombin based on human plasma and ZymoGenetics developed a synthetic form.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT